Company profile: Regeneron
1.1 - Company Overview
Company description
- Provider of innovative medicines, including EYLEA for eye diseases (age-related macular degeneration, diabetic retinopathy); Dupixent for atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis; REGEN-COV for COVID-19; Libtayo for certain skin cancers and non-small cell lung cancer; Praluent to lower LDL cholesterol; and Kevzara for rheumatoid arthritis.
Products and services
- Dupixent: pharmaceutical-grade treatment that delivers therapy for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis across these indications
- EYLEA: ophthalmic-grade medication used to treat eye diseases, including age-related macular degeneration and diabetic retinopathy, delivered for ophthalmic indications
- Kevzara: therapeutic-grade treatment for adults with moderately to severely active rheumatoid arthritis, delivered for clinical use in rheumatologic patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Regeneron
Cyclo Therapeutics
HQ: United States
Website
- Description: Provider of cyclodextrin-based therapeutics, including Trappsol® Cyclo™, a proprietary hydroxypropyl beta cyclodextrin formulation in clinical trials for Niemann-Pick Disease Type C1 and in a Phase 2b trial for early Alzheimer’s disease, leveraging data from an Expanded Access program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyclo Therapeutics company profile →
BioXcel Therapeutics
HQ: United States
Website
- Description: Provider of AI-driven drug re-innovation and therapeutics, including IGALMI, an FDA-approved sublingual film for acute agitation in adults with schizophrenia or bipolar I/II; BXCL501, an investigational dissolving dexmedetomidine film for agitation related to Alzheimer’s dementia and bipolar or schizophrenia; BXCL701, an oral innate immune activator under investigation for aggressive prostate, pancreatic, and other solid and liquid tumors; plus an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioXcel Therapeutics company profile →
Roquefort Therapeutics
HQ: United Kingdom
Website
- Description: Provider of pre-clinical anti-cancer therapeutics, including Midkine-targeting antibodies; antisense oligonucleotides to reduce Midkine in cancer cells; gene-editing RNA and mRNA therapies for solid tumors; STAT-6 siRNA therapeutics; and MK cell therapy with direct and NK cell-mediated action, advancing candidates toward clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Roquefort Therapeutics company profile →
Rosemont Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of oral liquid medicines for patients with swallowing difficulties, manufacturing and supplying 130+ formulations across therapeutic categories. Offers R&D for new low-excipient liquid medications, GMP and ICH Q10-compliant, regularly inspected manufacturing, international distribution to 27+ markets, and educational resources for healthcare professionals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rosemont Pharmaceuticals company profile →
Bristol Myers Squibb
HQ: United States
Website
- Description: Provider of pharmaceuticals, engaging in the discovery, development, licensing, manufacturing, marketing, distribution and sale of therapies, including cancer immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab); anticoagulant Eliquis (apixaban); oncology treatments Revlimid (lenalidomide) and Sprycel (dasatinib); and autoimmune therapy Orencia (abatacept).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bristol Myers Squibb company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Regeneron
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Regeneron
2.2 - Growth funds investing in similar companies to Regeneron
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Regeneron
4.2 - Public trading comparable groups for Regeneron
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →